MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (?)
Ratings Breakdown: 2 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $10.20 (12.71% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Show:
DateFirmActionRatingPrice TargetActions
5/25/2016Leerink SwannReiterated RatingHold$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Jefferies GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Robert W. BairdUpgradeNeutral -> Outperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Maxim GroupReiterated RatingBuy$11.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015William BlairReiterated RatingOutperform$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015JMP SecuritiesDowngradeOutperform -> Market Perform$24.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015Deutsche BankReiterated RatingBuy$25.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015BarclaysInitiated CoverageUnderweight$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/12/2014Wells FargoReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/21/2014Credit SuisseReiterated RatingNeutral$4.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/15/2014FBR & Co.Initiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2014Piper JaffrayUpgradeNeutral -> Overweight$5.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/26/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha